Cargando…

HLA and KIR genotyping correlates with relapse after T-cell-replete haploidentical transplantation in chronic myeloid leukaemia patients

BACKGROUND: Conflicting results have been reported regarding the predicative roles of alloreactive natural killer (NK) cells on the outcomes of transplantation in leukaemia patients. METHODS: We prospectively analysed the human leukocyte antigen (HLA) typing of donor–recipient pairs and the KIR typi...

Descripción completa

Detalles Bibliográficos
Autores principales: Zhao, X-Y, Chang, Y-J, Xu, L-P, Zhang, X-H, Liu, K-Y, Li, D, Huang, X-J
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group 2014
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4453853/
https://www.ncbi.nlm.nih.gov/pubmed/25077441
http://dx.doi.org/10.1038/bjc.2014.423
_version_ 1782374516472676352
author Zhao, X-Y
Chang, Y-J
Xu, L-P
Zhang, X-H
Liu, K-Y
Li, D
Huang, X-J
author_facet Zhao, X-Y
Chang, Y-J
Xu, L-P
Zhang, X-H
Liu, K-Y
Li, D
Huang, X-J
author_sort Zhao, X-Y
collection PubMed
description BACKGROUND: Conflicting results have been reported regarding the predicative roles of alloreactive natural killer (NK) cells on the outcomes of transplantation in leukaemia patients. METHODS: We prospectively analysed the human leukocyte antigen (HLA) typing of donor–recipient pairs and the KIR typing of the donors in 97 CML patients to address the predictive roles of NK cells in relapse undergoing T-cell-replete haploidentical transplantation. RESULTS: Patients with class I ligands for the donor-inhibitory KIR gene exhibited decreased molecular and haematologic relapse rates (P=0.003 and P=0.015, respectively). There was a significantly reduced risk of molecular and haematologic relapse in patients with HLA-C1C2 or C2C2 who accepted donors with KIR2DS1 or in patients with HLA-Bw4 who accepted donors with KIR3DS1 (‘recipient with relevant KIR ligand for donor-activating KIR', n=25), compared with the remaining transplants (n=72, P=0.009 and P=0.009, respectively). In addition, the presence of class I ligand in the recipients of donor-activating KIR contributed to a decreased relapse rate in patients lacking class I ligand in the recipient of donor-inhibitory KIR (P=0.04 and P=0.03, respectively). CONCLUSIONS: This study suggests that the presence of class I ligands for the donor-activating or donor-inhibitory KIR gene in the recipient might confer some protection against leukaemic relapse in T-cell-replete haploidentical transplantation.
format Online
Article
Text
id pubmed-4453853
institution National Center for Biotechnology Information
language English
publishDate 2014
publisher Nature Publishing Group
record_format MEDLINE/PubMed
spelling pubmed-44538532015-09-09 HLA and KIR genotyping correlates with relapse after T-cell-replete haploidentical transplantation in chronic myeloid leukaemia patients Zhao, X-Y Chang, Y-J Xu, L-P Zhang, X-H Liu, K-Y Li, D Huang, X-J Br J Cancer Clinical Study BACKGROUND: Conflicting results have been reported regarding the predicative roles of alloreactive natural killer (NK) cells on the outcomes of transplantation in leukaemia patients. METHODS: We prospectively analysed the human leukocyte antigen (HLA) typing of donor–recipient pairs and the KIR typing of the donors in 97 CML patients to address the predictive roles of NK cells in relapse undergoing T-cell-replete haploidentical transplantation. RESULTS: Patients with class I ligands for the donor-inhibitory KIR gene exhibited decreased molecular and haematologic relapse rates (P=0.003 and P=0.015, respectively). There was a significantly reduced risk of molecular and haematologic relapse in patients with HLA-C1C2 or C2C2 who accepted donors with KIR2DS1 or in patients with HLA-Bw4 who accepted donors with KIR3DS1 (‘recipient with relevant KIR ligand for donor-activating KIR', n=25), compared with the remaining transplants (n=72, P=0.009 and P=0.009, respectively). In addition, the presence of class I ligand in the recipients of donor-activating KIR contributed to a decreased relapse rate in patients lacking class I ligand in the recipient of donor-inhibitory KIR (P=0.04 and P=0.03, respectively). CONCLUSIONS: This study suggests that the presence of class I ligands for the donor-activating or donor-inhibitory KIR gene in the recipient might confer some protection against leukaemic relapse in T-cell-replete haploidentical transplantation. Nature Publishing Group 2014-09-09 2014-07-31 /pmc/articles/PMC4453853/ /pubmed/25077441 http://dx.doi.org/10.1038/bjc.2014.423 Text en Copyright © 2014 Cancer Research UK http://creativecommons.org/licenses/by-nc-sa/3.0/ From twelve months after its original publication, this work is licensed under the Creative Commons Attribution-NonCommercial-Share Alike 3.0 Unported License. To view a copy of this license, visit http://creativecommons.org/licenses/by-nc-sa/3.0/
spellingShingle Clinical Study
Zhao, X-Y
Chang, Y-J
Xu, L-P
Zhang, X-H
Liu, K-Y
Li, D
Huang, X-J
HLA and KIR genotyping correlates with relapse after T-cell-replete haploidentical transplantation in chronic myeloid leukaemia patients
title HLA and KIR genotyping correlates with relapse after T-cell-replete haploidentical transplantation in chronic myeloid leukaemia patients
title_full HLA and KIR genotyping correlates with relapse after T-cell-replete haploidentical transplantation in chronic myeloid leukaemia patients
title_fullStr HLA and KIR genotyping correlates with relapse after T-cell-replete haploidentical transplantation in chronic myeloid leukaemia patients
title_full_unstemmed HLA and KIR genotyping correlates with relapse after T-cell-replete haploidentical transplantation in chronic myeloid leukaemia patients
title_short HLA and KIR genotyping correlates with relapse after T-cell-replete haploidentical transplantation in chronic myeloid leukaemia patients
title_sort hla and kir genotyping correlates with relapse after t-cell-replete haploidentical transplantation in chronic myeloid leukaemia patients
topic Clinical Study
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4453853/
https://www.ncbi.nlm.nih.gov/pubmed/25077441
http://dx.doi.org/10.1038/bjc.2014.423
work_keys_str_mv AT zhaoxy hlaandkirgenotypingcorrelateswithrelapseaftertcellrepletehaploidenticaltransplantationinchronicmyeloidleukaemiapatients
AT changyj hlaandkirgenotypingcorrelateswithrelapseaftertcellrepletehaploidenticaltransplantationinchronicmyeloidleukaemiapatients
AT xulp hlaandkirgenotypingcorrelateswithrelapseaftertcellrepletehaploidenticaltransplantationinchronicmyeloidleukaemiapatients
AT zhangxh hlaandkirgenotypingcorrelateswithrelapseaftertcellrepletehaploidenticaltransplantationinchronicmyeloidleukaemiapatients
AT liuky hlaandkirgenotypingcorrelateswithrelapseaftertcellrepletehaploidenticaltransplantationinchronicmyeloidleukaemiapatients
AT lid hlaandkirgenotypingcorrelateswithrelapseaftertcellrepletehaploidenticaltransplantationinchronicmyeloidleukaemiapatients
AT huangxj hlaandkirgenotypingcorrelateswithrelapseaftertcellrepletehaploidenticaltransplantationinchronicmyeloidleukaemiapatients